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CNS damage can increase the susceptibility of the blood-brain barrier (BBB) to changes
induced by systemic inflammation. The aim of this study is to better understand BBB per-
meability in patients with MS and to examine whether compromised BBB integrity in some of
these patients is associated with CNS damage and systemic inflammation.
Methods
Routine CSF measurements of 121 patients with MS were analyzed including number and type
of infiltrating cells, total protein, lactate, and oligoclonal bands, as well as intrathecal production
of immunoglobulins and CSF/serum quotients for albumin, immunoglobulins, and glucose. In
addition, in a subcohort of these patients, we performed ex vivo immunophenotyping of CSF-
infiltrating and paired circulating lymphocytes using a panel of 13 monoclonal antibodies, we
quantified intrathecal neurofilament light chain (NF-L) and chitinase 3-like 1 (CHI3L1), and
we performed intrathecal lipidomic analysis.
Results
Patients with MS with abnormal high levels of albumin in the CSF showed a distinct CSF cell
infiltrate and markers of CNS damage such as increased intrathecal levels of NF-L and CHI3L1
as well as a distinct CSF lipidomic profile. In addition, these patients showed higher numbers of
circulating proinflammatory Th1 and Th1* cells compatible with systemic inflammation. Of
interest, the abnormally high levels of albumin in the CSF of those patients were preserved over
time.
Conclusions
Our results support the hypothesis that CNS damage may increase BBB vulnerability to
systemic inflammation in a subset of patients and thus contribute to disease heterogeneity.
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Systemic inflammation can influence blood-brain barrier
(BBB) permeability and increase vesicular trafficking of al-
bumin from serum to the CNS.1 In animal models of Alz-
heimer disease,2 ischemic stroke,3 and MS,4,5 it has been
observed that the effect of systemic inflammation on BBB
permeability was higher in animals with these CNS patholo-
gies, suggesting that brain damage could increase the sus-
ceptibility of the BBB to changes induced by systemic
inflammation. Consistent with these findings, a human study
demonstrated a link between markers of systemic in-
flammation and markers of increased BBB permeability, in
particular high CSF/serum albumin quotient (QAlb) in in-
dividuals with abnormal CSF measures but not in those
without. Because abnormal CSF measures most likely reflect
CNS alterations, these results support a role of CNS damage
in increasing BBB susceptibility to systemic inflammation.6
MS is a heterogeneous immune-mediated neurologic disease
that damages the CNS. This damage might increase the sus-
ceptibility of the BBB to changes induced by a systemic in-
flammation in some patients and contribute to MS
heterogeneity. Supporting such an association between CNS
damage and changes in BBB permeability, it has been ob-
served that high QAlb and other CSF markers of compro-
mised BBB integrity in patients with MS are accompanied by
brain atrophy and faster increase in disability.7,8
To better understand BBB permeability inMS and its putative
association with CNS damage and systemic inflammation, we
performed a detailed characterization of CSF and paired




Paired CSF and blood samples were collected from 121 un-
treated patients with MS (20 patients with radiologically or
clinically isolated syndrome, 91 with relapsing-remitting MS,
and 10 with progressive MS), 40 controls with other non-
inflammatory neurologic diseases (ONIND), and 21 with
other inflammatory neurologic diseases (OIND). All CSF
samples were obtained for diagnostic purposes. Demographic
Glossary
BBB = blood-brain barrier; CHI3L1 = chitinase 3-like 1; FADS3 = fatty acid desaturase 3; HLA = human leukocyte antigen;
IFN = interferon; Ig = immunoglobulin; NF-L = neurofilament light chain; OIND = other inflammatory neurologic diseases;
ONIND = other noninflammatory neurologic diseases; PC = phosphatidylcholine;QAlb = serum albumin quotient;QNorm =
normal QAlb; RBC = red blood cell; SAdienine = sphingadienine; SM = sphingomyelin.
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Table 1 Demographic and Clinical Features of Patients With MS and Controls
MS cohort Controls
Main Sub-1 Sub-2 ONIND OIND
No. of patients 121 79 36 40 21
Female/male ratio 2.02 2.16 2.3 0.72 0.72
Age (y) 35.9 ± 9.9 35.9 ± 10.2 37.5 ± 11.4 40.7 ± 12.6 45.2 ± 9.5
Disease duration (mo) 25.5 ± 48.3 26 ± 51.7 29.4 ± 55.1
MS main cohort
With increased QAlb Without increased QAlb p Value
No. of patients 30 91
Female/male ratio 1.1 2.5
Age at CSF puncture (y) 35.2 ± 10.2 36.6 ± 10 ns
Age at onset (y) 32.1 ± 8.3 34.4 ± 9.8 ns
RIS/CIS (%) 33.4 40
RRMS (%) 56.6 53.7
PMS (%) 10 6.3
Disease duration (mo) 27.6 ± 49.2 26.5 ± 48.3 ns
Time since last relapse (d) 119.3 ± 317.7 287.8 ± 642.5
Clinically activea (%) 73.3 54.9
Gd contrast-enhancing lesionsa (%) 60 48.7
Lesions location
Optic neuritis (%) 28.6 18.6
Myelitis (%) 25 19.7
Brainstem (%) 7.1 8.1
Several (%) 39.3 53.6
Expanded Disability Status Scale 2.25 ± 1.8 1.7 ± 1.5
HLADR15 (%) 41.3 50.5
CSF
CSF OCB type II (%) 90 81
Albumin quotient 7.94 ± 1.03 4.24 ± 1.81 <0.0001
IgA index 0.37 ± 0.36 0.32 ± 0.27 ns
IgG index 0.79 ± 0.38 1.11 ± 0.87 ns
IgM index 0.14 ± 0.21 0.16 ± 0.16 ns
Patients with IgG(loc) >10% (%) 35.7 52.9
Total intrathecal protein (mg/L) 619.0 ± 159.7 392.8 ± 88.88 <0.0001
Intrathecal lactate (mmol/L) 1.64 ± 0.20 1.61 ± 0.25 ns
Glucose quotient 0.65 ± 0.09 0.66 ± 0.11 ns
Albumin in serum (g/L) 46.08 ± 3.57 45.63 ± 5.03 ns
Abbreviations: CIS = clinically isolated syndrome; Ig = immunoglobulin; OCB = oligoclonal band; OIND = other inflammatory neurologic diseases; ONIND =
other noninflammatory neurologic diseases; PMS = progressive MS; QAlb = serum albumin quotient; QNorm = normal QAlb; RIS = radiologically isolated
syndrome; RRMS = relapsing-remitting MS.
Mean ± SD is shown.
a Clinically active means during a relapse, i.e., in the presence of new neurologic symptoms lasting at least 24 hours and with no evidence of signs/symptoms
of systemic inflammation within 3 months before or after lumbar puncture.
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and clinical characteristics are summarized in table 1.
Patients were recruited from the Neuroimmunology and
MS Research Section, Neurology Clinic, University Hos-
pital Zurich. MS diagnosis was based on the revised
McDonald criteria.9 Patients who had not received ste-
roids at least 4 weeks before enrollment or any immuno-
modulatory or immunosuppressive agent during the last 3
months were considered untreated and included in the
study. In particular, 97 patients were never treated, 16
patients were previously treated only with steroids, 4 pa-
tients received steroids and an immunomodulatory or
immunosuppressive agent (1 patient, interferon [IFN]
β-1a; 1 patient, glatiramer acetate; and 2 patients, dimethyl
fumarate), and 4 patients received only an immunomod-
ulatory or immunosuppressive agent (1 patient, IFNβ-1a;
2 patients, glatiramer acetate; and 1 patient, dimethyl
fumarate).
Standard Protocol Approvals, Registrations,
and Patient Consents
The Cantonal Ethics Committee of Zurich approved the
study procedures (EC-No. 2013-0001). Informed consent
was obtained from all patients or relatives.
Routine CSF and Serum Measures
CSF-infiltrating cells were counted with a Fuchs Rosenthal
counting chamber under the microscope within 1 hour after
lumbar puncture. CSF total protein as well as CSF and serum
albumin, immunoglobulin (Ig) G, IgM, and IgA were de-
termined by immunonephelometry. Quotients (Q) were de-
fined as Q = (concentration in CSF [mg/L]/concentration in
serum [g/L]). Because QAlb increases with age, we calculated
a maximum normal QAlb (QNorm) for each patient that
takes into account the age at lumbar puncture (QNorm =
[age/15] + 4 × 10−3).10 Intrathecal Ig synthesis (Ig(loc)) was
calculated using hyperbolic functions according to Reiber and
expressed as percentage (%).11 Identification of CSF-
restricted oligoclonal bands was performed by isoelectric
focusing.
HLA Typing
Patients were typed for human leukocyte antigen (HLA) class
I (A* and B*) and II (DRB1*, DRB3*, DRB4*, DRB5*,
DQA1* and DQB1*) molecules using high-resolution HLA
sequence-based typing at Histogenetics LLC, Ossining, NY.
Isolation of DNA from whole blood with a final concentration
of 15 ng/μL was performed with a standard DNA isolation
Figure 1 Characterization of CSF From Patients With MS With and Without Increased QAlb
(A) Graph showsQAlbminusQNorm. Patients inwhich this difference is positive are showed in red and those in which is negative in black. Comparison between
patientswith andwithout increasedQAlb of: (B) quotients and Igs(loc) expressed as percentage (%) for IgA, IgG, and IgMand (C) CSF-infiltrating cells (number of
cells/μL) and frequency (%) of lymphocytes and monocytes analyzed under the microscope. (D) Correlation between number of CSF-infiltrating cells and
IgG(loc) expressed as percentage (%). Graphs (A–D) represent the main cohort of 121 patients with MS. Each dot in the graphs corresponds to 1 patient, and
bars show the mean. A t test for normally distributed variables and U test (Mann-Whitney) for non-normally distributed variables was used to compared
patients. Linear correlation was tested using Pearson for normally distributed and Spearman r for non-normally distributed variables. Statistical significance
(* p < 0.05, ** p < 0.01, and **** p < 0.0001) is shown. Ig = immunoglobulin; QAlb = serum albumin quotient; QNorm = normal QAlb.
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protocol using a Triton lysis buffer and proteinase K
treatment.
Flow Cytometric Immunophenotyping
Flow cytometric immunophenotyping of CSF-infiltrating and
paired circulating lymphocytes was performed as previously
reported.12 Briefly, a minimum of 10,000 CSF-infiltrating cells
were concentrated by centrifugation and processed in the first
hour after collection. Blood circulating cells were obtained
from 800 μL of peripheral blood after lysis of red blood cells
(RBCs) using RBC Lysis buffer (BioLegend, San Diego, CA).
Cells were stained with a cocktail of 13monoclonal antibodies.12
SPHERO AccuCount Particles (Sperotech, Inc., Lake Forest,
IL) were added to determine absolute counts following
manufacturer’s instructions. Sample acquisition was per-
formed in an LSR Fortessa cytometer (BD Biosciences,
Franklin Lakes, NJ), and data were analyzed using FACSDiva
(BD) and FlowJO (TreeStar Inc., Ashland, OR) software.
The gating strategy is summarized in figure e-1 (links.lww.
com/NXI/A413).
Legend Plex and ELISAs
Cytokines directly in the CSF were measured using the Hu-
man T Helper Cytokine Panel LEGENDplex bead-based
immunoassay (BioLegend) according to the manufacturer’s
instructions.
Intrathecal neurofilament light chain (NF-L) and chitinase
3-like 1 (CHI3L1) proteins were quantified in CSF samples
Figure 2 Characterization of CSF-Infiltrating Cells and Markers of CNS Damage in Patients With MS With and Without
Increased QAlb
(A) Comparison between patients with and without increased QAlb of frequencies of Th2-A (CCR6- CCR4+ CRTH2−) in CM CD28
+ CD27-, EM CD28+ CD27-, EM
CD28-, and TEMRACD28+CD27+ CD4+ CSF-infiltrating T cells. (B) Comparison between patients with IgG(loc) (>10%) andwithout IgG(loc) (<10%) of frequencies
of EM CD28+ CD27- CD4+ CSF-infiltrating cells with a Th2-A (CCR6- CCR4+ CRTH2−) functional phenotype. Correlation between these frequencies and IgG(loc)
expressed as %. (C) Comparison between patients with and without increased QAlb of frequencies of Th1 (CCR6- CCR4- CRTH2−) cells in EM CD28- CD4
+ CSF-
infiltrating T cells and amount of IFNγ expressed as pg/mL present in the CSF of 30 patients as well as correlation between the amount of IFNγ and QAlb. (D)
Comparison of NF-L and CHI3L1 intrathecal concentration between patients with and without increased QAlb. (E) Correlation between the intrathecal
concentration of these 2biomarkers andQAlb and also between themselves. Graphs (A–C) represent subcohort 1 of 79 patientswithMS, and frequencies have
been obtained by ex vivo immunophenotyping, and (E–D) represent themain cohort of 121 patients withMS. Each dot in the graphs corresponds to 1 patient,
and bars show the mean. Patients with increased QAlb are shown in red. T test t test for normally distributed variables and U test (Mann-Whitney) for non-
normally distributed variables was used to compared patients. Linear correlation was tested using Pearson for normally distributed and Spearman r for non-
normally distributed variables. Statistical significance (*p < 0.05, **p < 0.01) is shown.
Neurology.org/NN Neurology: Neuroimmunology & Neuroinflammation | Volume 8, Number 2 | March 2021 5
Figure 3 Lipidomic Profile in Patients With MS With and Without Increased QAlb
(A) Heatmap of the 10 statisticallymost significant altered lipid species between patients withMSwith andwithout increased QAlb. The abundance of the lipid
species is qualitatively represented by color intensity for each of the 36 patients with MS (subcohort 2). Mean, SD, and p values of the group comparisons are
shown. (B) Correlations between QAlb and the intrathecal concentration for 6 of the identified lipid species. Linear correlation between variables was tested
using Pearson correlation, and p values are shown. (C) Ratios between mean CSF concentration of lipid species in patients with MS and the concentration in
plasma from a reference control cohort with 24 healthy controls. Marked in red are the 4 SM and 5 PC species that were significantly more abundant in
patients with MS with increased QAlb. Ig = immunoglobulin; QAlb = serum albumin quotient.
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by ELISA (Human Diagnostics, Umea, Sweden, and Micro-
Vue, Athens, OH, respectively) according to the manufac-
turer’s instructions.
Lipid Extraction and Lipidomics
Lipid extraction was performed as previously described13
with some modifications. The MMC solvent (methanol:
methyl tert-butyl ether: chloroform, 4:3:3, vol:vol:vol) was
supplemented with the SPLASH mix internal standard and
additional internal standards (all from Avanti Polar Lip-
ids): d7-sphinganine (SPH d18:0), d7-sphingosine (SPH
d18:1), dihydroceramide (Cer d18:0/12:0), ceramide
(Cer d18:1/12:0), glucosylceramide (GluCer d18:1/8:0),
sphingomyelin (SM d18:1/12:0), and d7-sphingosine-1-
phosphate (S1P d18:1). Liquid chromatography was per-
formed according to Ref. 14 with some modifications.
Lipids were separated using a C30 Accucore LC column
(150 × 2.1 mm, 2.6 μm particle size) and a Transcend
UHPLC pump (Thermo Fisher Scientific). Mass spec-
trometry analysis was performed on a hybrid quadrupole-
orbitrap mass spectrometer (Q-Exactive; Thermo Fisher
Scientific). Lipid identification criteria were (1) resolution
with an accuracy of 5 ppm from the predicted mass at a
resolving power of 70,000 at 200 m/z, (2) isotopic
Figure 4 Immunophenotyping of Peripheral Circulating Lymphocytes in PatientsWithMSWith andWithout IncreasedQAlb
Comparison, between patients with (red) andwithout (black) increased QAlb, of number of CD8
+ CMCD28+ Th1 (CCR6- CCR4- CRTH2-) and Th1* (CCR6+ CCR4-
CRTH2-), CD4+ CM CD28+ CD27+ Th1 (CCR6- CCR4- CRTH2-) and Th1* (CCR6+ CCR4- CRTH2-), CD4+ EM CD28+ CD27+ Th1 (CCR6- CCR4- CRTH2-) and Th1*
(CCR6+ CCR4- CRTH2-), and CD4+ TEMRACD28+ Th1 (CCR6- CCR4- CRTH2-) and Th1* (CCR6+ CCR4- CRTH2-) in patientswith andwithout increasedQAlb, as well
as the correlation between these cell counts andQAlb. All graphs represent subcohort 1 consisting of 79 patientswithMS. Each dot in the graph corresponds to
a single patient, and bars show themean. T test t test for normally distributed variables andU test (Mann-Whitney) for non-normally distributed variables was
used to compared patients. Linear correlation was tested using Pearson for normally distributed and Spearman r for non-normally distributed variables.
Statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001) is shown. Statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p <
0.0001) is shown. QAlb = serum albumin quotient.
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distribution, (3) expected retention time, and (4) frag-
mentation pattern.
Data analysis was performed using TraceFinder 4.1 (Thermo
Fisher Scientific) for peak picking, annotation, and matching
to an in-house lipid database.
Statistics
For comparison of 2 groups of patients, we used the un-
paired t test for normally distributed variables and the U test
(Mann-Whitney) for non-normally distributed variables.
Linear correlation between variables was tested using Pear-
son for normally distributed and Spearman r for non-
normally distributed variables. The significance level was set
at p < 0.05.
Data Availability
Any data not published within the article because of space
limitations will be shared as anonymized data by request from
any qualified investigator for purposes of replicating proce-
dures and results.
Results
Patients With MS With Increased QAlb
We determined the QAlb in our cohort of 121 patients with
MS, and, assuming that this parameter increases with age, we
marked a maximum QNorm for each patient as explained in
M&M. We defined patients with increased QAlb as patients
having a QAlb > QNorm. We used increased QAlb as in-
dicator of BBB permeability although we are aware that it is
not a perfect measurement because other factors such as al-
tered CSF flow due to meningeal inflammation might in-
fluence it.15 Based on this definition of increased QAlb, 30
(24.8%) of patients with MS had an increased QAlb and 91
(75.2%) not (figure 1A). Demographic and clinical features of
these patients are summarized in table 1. None of these pa-
rameters showed significant differences between patients with
Figure 5 QAlb Analysis Over Time
(A and B) Linear representations of QAlbminus QNorm values
(B) and number of CSF-infiltrating cells per μL (C) over time
in a cohort of 33 patientswithMS fromwhich CSF samples at
different time points were available. X-axis represents time
in months, and Y-axis represents QAlb-QNorm and number of
CSF-infiltrating cells per μL. The number of patients in each
graph is indicated. The dotted line represents the limit for
normal values (0 for QAlb-QNorm and 4 for number of CSF-
infiltrating cells). Patients who maintain high levels over
time are shown in red, those who maintain low levels in
black, and those who change the levels in gray. Fine lines
and circles correspond to untreated patients. Patients
treated between lumbar punctures are shown with bold
lines and squares (dimethyl fumarate), triangles (natalizu-
mab), and diamonds (fingolimod). QAlb = serum albumin
quotient; QNorm = normal QAlb.
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MS with and without increased QAlb. HLA typing of these
patients demonstrated that the expression of the MS-
associated DR15 haplotype was also comparable in both
groups of patients (table 1). We did not find any HLA class I
or class II molecule over- or under-represented in patients
with increased QAlb (data not shown).
CSF Measures in Patients With MS With
Increased QAlb
IgA quotients were much higher in patients with MS with
increased QAlb, IgG quotients were also significantly higher
in these patients although to a lesser extent, and minimal
differences were found for IgM quotients (figure 1B). In
contrast, the indices for these 3 Igs corrected for albumin
concentration (see M&M) were comparable in both groups
of patients suggesting a strong association between the traffic
of albumin and IgA and to a lesser extent IgG (table 1).
Regarding the Igs(loc), only IgG(loc) was significantly lower
in patients with increased QAlb (table 1 and figure 1B). Total
CSF protein was significantly higher in patients with MS with
increased QAlb, whereas serum albumin, intrathecal lactate,
and glucose quotient were comparable in patients with and
without increased QAlb (table 1).
CSF-Infiltrating Cells in Patients With MS With
Increased QAlb
CSF analysis under the microscope showed comparable num-
bers of CSF-infiltrating cells in patients with and without in-
creased QAlb, but different composition. CSF from patients
with increased QAlb contains less lymphocytes but significantly
more monocytes (figure 1C). This different cell composition of
the CSFmight underlie the lower correlation between IgG(loc)
and number of CSF-infiltrating cells in patients with increased
QAlb (figure 1D). Flow cytometry immunophenotyping of
CSF and paired blood from a subcohort of 79 patients with MS
(table 1, subcohort 1)12 allowed a detailed characterization of
Figure 6 Characterization of CSF-infiltrating Cells in Controls With and Without Increased QAlb
(A and B) QAlb minus QNorm has been used like in patients with MS to differentiate controls with (in red) and without (in black) increased QAlb. Comparison
between controls (ONIND [n = 40] (A) and OIND [n = 21] (B)) with and without increased QAlb of IgA and IgG quotient, CSF-infiltrating cells, and frequency of
TH2-A (CCR6- CCR4+ CRTH2-) and TH2-B (CCR6- CCR4+ CRTH2+) in CD4+ CMCD28+ CD27- and in CD4+ EMCD28+ CD27- CSF-infiltrating cells. In all graphs, each
dot corresponds to 1 patient, and bars show themean. T test t test for normally distributed variables andU test (Mann-Whitney) for non-normally distributed
variables was used to compared patients. Statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001) is shown. Statistical significance (*p <
0.05, **p < 0.01, and ****p < 0.0001) is shown. QAlb = serum albumin quotient; QNorm = normal QAlb.
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CSF-infiltrating and circulating lymphocytes (table e-1, links.
lww.com/NXI/A413). Although most of the CSF-infiltrating
cells in patients with and without increased QAlb showed
similar frequencies, we found that CD4+ T cells with a Th2-A
functional phenotype, based on the combination of chemokine
receptors (CCR6− CCR4+ CRTh2−), and the following dif-
ferent maturation states: (1) CM and EM CD28+ CD27−
CD4+ T cells, that have downregulated CD27 most likely
following repetitive stimulation with antigen,16 (2) EM
CD28−and (3) TEMRA CD28+ CD27+, were all significantly
reduced in patients with increased QAlb (table e-1, figure e-2A,
and figure 2A). Patients with MS with increased QAlb showed
lower levels of these Th2 CD4+ T cells than patients without
increased QAlb independently of disease activity and most
likely clinical form of the disease (data not shown). Th2 cells
are required for humoral immunity, and accordingly, we found
Figure 7 Characterization of Peripheral Circulating Cells in Controls With and Without Increased QAlb
(A and B) Comparison between controls (ONIND [n = 40] (A) and OIND (n = 21) (B)) with and without increased QAlb of number of: CD8+ CM CD28+ Th1
(CCR6- CCR4- CRTH2-) and Th1* (CCR6+ CCR4- CRTH2-), CD4+ CMCD28+ CD27+ Th1 (CCR6- CCR4- CRTH2-) and Th1* (CCR6+ CCR4- CRTH2-), CD4+ EMCD28+
CD27+ Th1 (CCR6- CCR4- CRTH2-) and Th1* (CCR6+ CCR4- CRTH2-), and CD4+ TEMRA CD28+ Th1 (CCR6- CCR4- CRTH2-) and Th1* (CCR6+ CCR4- CRTH2-)
circulating cells. Cell counts have been determined using SPHEROTM AccuCount Particles. In all graphs, each dot corresponds to 1 patient, and bars show
the mean. T test t test for normally distributed variables and U test (Mann-Whitney) for non-normally distributed variables was used to compared
patients.
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a significant association between the frequencies of EMCD28+
CD27− CD4+ Th2-A cells and IgG(loc) (%) (figure 2B). Pa-
tients with increased QAlb also showed significantly higher
frequencies of EM CD28− TH1 cells as well as significantly
higher amounts of IFNγ in the CSF that correlated with QAlb
(figure 2C). None of the other 12 cytokines showed differences
between patients with and without increased QAlb (figure
e-2B). The frequencies of these cell types in peripheral blood
were comparable between patients with and without increased
QAlb (table e-1 and figure e-2C).
Markers of CNS Damage in Patients With MS
With Increased QAlb
Because previous studies associated increased QAlb with
higher disability in patients withMS,7,8we explored indicators
of CNS damage in our cohort of 121 patients with MS using 2
promising biomarkers: NF-L, a cytoskeletal component of
neurons that is very abundant in axons,17 and it has been
associated with BBB integrity,18 and CHI3L1, a glycoprotein
secreted by activated glia.19Our results demonstrated that the
intrathecal quantity of both biomarkers was statistically higher
in the CSF of patients with increased QAlb (figure 2D), and
their amount correlated with QAlb and with each other as
already reported20 (figure 2E). The higher amount of NF-L
and CHI3L1 in patients with MS with increased QAlb does
not seem to be related to disease activity or clinical form of the
disease (data not shown), although the low number of pa-
tients with radiologically isolated syndrome/clinically isolated
syndrome and progressive MS forms limits conclusions.
Next, we used liquid chromatography/mass spectrometry to an-
alyze the lipidomic profile in a subcohort of 36 patients with MS
(table 1, subcohort 2). Because the brain has the second highest
lipid content after adipose tissue, lipids are the main components
of myelin sheaths and changes in lipid metabolism have been
observed in damaged cells, we used lipidomics to explore CNS
damage. The total lipid content inCSF reflected about 0.1%–0.5%
of the plasma levels. In total, we identified 510 different lipid
species inCSF ofwhich 105 passed theQCcriteria (R2>0.9 +CV
<20%). The intrathecal concentrations of 10 species were signif-
icantly higher in the CSF of patients with increased QAlb (figure
3A). Themajority of these species showed a significant correlation
with QAlb, whereas the strongest association was seen for the
phosphatidylcholines (PCs) PC (38:3) and PC (40:5) and the
sphingomyelins (SMs) SM (d40:3), SM (d41:2), SM (d42:2),
and SM (d42:3) (figure 3B). Comparing the lipid profile in the
CSF from patients with MS with the plasma levels from an in-
dependent reference cohort (n = 32) showed a distinct CSF/
plasma ratio for the individual species indicating that this increased
in the intrathecal lipids was selective and not simply caused by
diffusion from plasma (figure 3C).
Peripheral Inflammation in Patients With MS
With Increased QAlb
Because previous studies associated increased QAlb with sys-
temic inflammation in patients with abnormal CSF measures,6
we quantified peripheral blood lymphocytes inMS subcohort 1
(table 1) using flow cytometry immunophenotyping and
counting beads. Although the frequencies of the lymphocyte
subtypes did not show significant differences between patients
with and without increased QAlb, the real counts of several of
these cells did (table e-1, links.lww.com/NXI/A413). Patients
with increased QAlb had significantly higher counts of circu-
lating CD3+ T cells, CD8+, and in particular CD4+ cells (table
e-1). For each T-cell type, particularly CM and EM cells were
increased (table e-1). Regarding the functional phenotype of
these T cells, CMCD28+CD8+T cells and CM, EM, as well as
TEMRA CD28+ CD27+ CD4+ T cells, all with Th1 (CCR6−
CCR4− CRTh2−) and Th1* (CCR6+ CCR4− CRTh2−)
functional phenotypes were significantly increased in the blood
of patients with increased QAlb (figure 4). In addition, a sta-
tistically significant correlation between the number of these
T-cell subtypes in blood and the QAlb was observed (figure 4).
Disease activity and the clinical form of the disease does not
seem to influence the higher frequency of these cells in pa-
tients with MS with increased QAlb (data not shown).
Increased Albumin Quotient Is Preserved
Over Time
CSFs from 33 patients with MS were analyzed at different
time points. All patients were untreated at the first time point.
Eleven patients (33.3%) had increased QAlb at the first time
point and 10 of these patients (83.3%) maintained increased
QAlb over time, in 2 patients for even more than 40 months
(figure 5A). Six of these patients received treatment between
lumbar punctures (1 dimethyl fumarate, 3 fingolimod, and 2
natalizumab), whereas 4 patients remained untreated. The
increased QAlb disappeared only in 1 patient after 58 months
without treatment. Of the 22 patients without increased QAlb
at the first time point, only 2 showed increased QAlb in
subsequent analyses (figure 5A). Although some treatments
can have an effect on BBB permeability and reduced QAlb
values, our results suggest that in patients with increasedQAlb
the reduction to normal QAlb values is not easy and, if pos-
sible, it might take time.
We analyzed the number of CSF-infiltrating cells in the same
samples. Fifteen patients (45.45%) had more than 4 CSF-
infiltrating cells per μL at the first time point, but only 6 of these
patients (40%) maintained elevated CSF cell counts over time
and no patient for more than 20 months (figure 5B).
Regarding the 16 patients with low CSF cell counts at the first
time point, only 2 patients showed increased numbers over
time (figure 5B).
Increased QAlb in ONIND and OIND
Finally, we examined whether the differences in CSF-infiltrating
and circulating lymphocytes between patients with MS with and
without increased QAlb were also present in controls (table 1).
Using the definition of increased QAlb as QAlb > QNorm, we
identified 9 (22.5%) ONIND and 10 (47.6%) OIND patients
with increased QAlb and 31 (77.5%) ONIND and 11 (52.4%)
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OIND patients without (figure 6, A and B). As observed in
patients with MS, all controls with increased QAlb showed sig-
nificantly higher intrathecal IgA and IgG (figure 6, A and B). The
number of CSF-infiltrating cells was comparable between
ONIND controls with and without increased QAlb, whereas it
was significantly higher in OIND controls with increased QAlb
(figure 6, A and B). The differences in CSF-infiltrating and
peripheral blood lymphocytes that we observed in patients with
MSwith and without increased QAlb were not found in controls
(figure 7, A and B).
Discussion
Different studies2–6 have suggested that CNS damage may
increase the susceptibility of the BBB to changes induced by
systemic inflammation such as increased vesicular trafficking
of albumin. MS is a complex immune-mediated disease that
affects the CNS and BBB permeability.21 In some patients
with MS, CNS damage and systemic inflammation may co-
exist and influence BBB function. With the aim to better
understand BBB permeability in MS and to investigate a
putative role of CNS damage and systemic inflammation on
BBB dysfunction, we identified patients with MS with in-
creased QAlb and characterized them in detail. The com-
parison of demographic and clinical features between patients
with MS with and without increased QAlb did not reveal any
statistically significant difference, although the limited clinical
data did not allow a definitive statement. Unfortunately,
neither longitudinal MRI data nor longitudinal disability
measures were available from our cohort to confirm the
previously reported association between increased QAlb and
greater deterioration in patients with MS.7,8
However, the detailed analysis of CSF revealed interesting
differences between patients with and without increased
QAlb. Patients with MS with increased QAlb showed signif-
icantly higher intrathecal levels of IgA and IgG and to a lesser
extent of IgM. Because the indices of IgA and IgG, in which
the values are corrected for the traffic of albumin, were
comparable between patients, our results suggest that the
passage of IgA and IgG across the BBB is most likely associ-
ated with the passage of albumin. IgM with its pentameric
nature, much larger size, and molecular weight may not use
vesicular trafficking. Patients with MS with increased QAlb
also showed reduced IgG(loc). Regarding the CSF infiltrate,
although the number of infiltrating cells was comparable in
patients with and without increased QAlb, the cellular com-
position was different. Patients with MS with increased QAlb
contained significantly more monocytes.
Because monocytes are not involved in antibody production,
the correlation between CSF-infiltrating cells and IgG(loc) was
significantly lower in patients with increased QAlb. Of interest,
mediators involved in BBB dysfunction such as reactive oxy-
gens species22 and matrix metalloproteinase 923 are produced
by monocytes. Our ex vivo immunophenotyping of CSF-
infiltrating lymphocytes demonstrated that patients with MS
with increased QAlb and reduced IgG(loc) also showed sig-
nificantly lower frequencies of CD4+ T cells with a Th2 func-
tional phenotype. In particular, the following CD4+ T cell
subsets: CM and EMCD28+ CD27− CD4+ T cells, which may
be relevant due to their downregulation of CD27 after re-
petitive stimulation with antigen,16 EM CD28− and TEMRA
CD28+ CD27+ CD4+ T cells. Th2 cells are relevant for hu-
moral immunity, and accordingly, we demonstrated an asso-
ciation between these cells and intrathecal IgG synthesis. Th2
cells, in addition to their role in humoral immunity, may also
have a protective anti-inflammatory role as has been assumed in
some MS clinical trials aimed to deviate immune responses
from Th1 toward Th2.24 Their reduction in patients with MS
with increased QAlb might thus have harmful consequences.
We also found that EM CD28− CD4+ T cells with a Th1
functional phenotype were significantly higher in patients with
increased QAlb as well as the amount of IFNγ in the CSF.
Long-term memory CD4+ CD28− T cells can produce high
amounts of IFNγ in the absence of costimulation and showed
increased survival and proliferation capacity after activation.25
Their putative role in MS is supported by their expansion in a
subgroup of patients with MS and their myelin basic protein
specificity.26 Immunophenotyping of paired blood samples did
not show the same differences that have been observed be-
tween patients by CSF analyses. It is therefore unlikely that
mere bystander traffic is responsible for the changes in the CSF.
The higher concentration of IgG and IgA observed in patients
with MS with increased QAlb, as well as the higher frequency
of monocytes, the higher amount of IFNg and the lower fre-
quency of potentially protective Th2 CD4+ T cells might fa-
cilitate CNS damage in these patients. Accordingly, our results
demonstrate that patients with MS with increased QAlb show
significantly higher levels of biomarkers of CNS damage and
inflammation such as NF-L and CHI3L1 and support previous
studies, in which increasedQAlb in patients withMSwas found
to be associated with atrophy and greater deterioration7,8 as
well as higher levels of serumNF-L.18 In addition, we identified
10 intrathecal lipid species that are more abundant in patients
with MS with increased QAlb.
Although we do not know the underlying mechanisms, the
increase of these lipids may be involved in CNS damage. Two
of the 4 identified SM species contained a Sphingadienine
(SAdienine) long chain base, which is formed as a down-
stream product of sphingosine via fatty acid desaturase 3
(FADS3).27 The increase in SAdienine-based SM suggests a
possible role of FADS3 in this process. Of interest, a previous
study linked changes in the same SAdienine-based SM species
to an increased activity of acid sphingomyelinase, which
converts SM to ceramide.28 The activation of the acid
sphingomyelinase/ceramide system has been demonstrated
to be a central step for the development of EAE.29
Regarding a putative association between systemic in-
flammation and BBB permeability in patients with MS, our
results demonstrate that several lymphocyte populations, in
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particular T cells with a Th1 and Th1* functional phenotype,
were significantly more abundant in patients with MS with
increased QAlb and cell counts correlated with QAlb. Of in-
terest, this association was not observed in controls patients
with ONIND and OIND diseases, suggesting that the type of
systemic inflammation that might influence BBB permeability
most likely differs between pathologies. Unfortunately, the
usual and easy-to-determine markers of systemic inflammation
such as C-reactive protein or neutrophil counts were not
available from the blood taken at the time of lumbar puncture.
The coexistence of markers of CNS damage and systemic
inflammation in patients with MS with increased QAlb sup-
ports a putative role of CNS damage in increasing BBB vul-
nerability to systemic inflammation in these patients. Because
the capacity of remyelination is limited and neuroregenerative
treatments are missing, we can assume that CNS damage
might persist over time. Accordingly, increased QAlb in pa-
tients with MS was also preserved over time even after initi-
ating immunomodulatory treatments. It will be interesting to
see in the future if treatments or treatment combinations with
neuroregenerative potential have an effect on QAlb. Finally,
given that CNS damage and systemic inflammation vary
among patients with MS and influence BBB permeability, also
it will be of interest to examine their impact on MS hetero-
geneity and its value in patient classification. Patients with
increasedQAlbmight especially profit from a better control of
systemic inflammation as well as from neuroprotective/
neuroregenerating treatment approaches.
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